BRAINSTORM CELL THERAPEUTICS (BCLI) Stock News

USA - NASDAQ:BCLI - US10501E3009 - Common Stock

1.17 USD

-0.03 (-2.5%)

Last: 7/17/2025, 8:04:41 PM

0.67 USD

-0.5 (-42.74%)

After Hours: 7/17/2025, 8:04:41 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BCLI Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Halper Sadeh LLC

Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights

a month ago - By: Grabar Law Office - Mentions: ANRO FLYW IBTA

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf

3 months ago - By: The Motley Fool

Brainstorm Posts 43% EPS Gain in Q2

3 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Benzinga

A Peek at Brainstorm Cell's Future Earnings

7 months ago - By: Benzinga

A Preview Of Brainstorm Cell's Earnings

3 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

4 months ago - By: Stocktwits

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time'

4 months ago - By: Brainstorm Cell Therapeutics Ltd.

BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB

5 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

5 months ago - By: BrainStorm Cell Therapeutics Inc. - Mentions: PLUR

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

6 months ago - By: Stocktwits - Mentions: PFE

Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours

6 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

6 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

6 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025

6 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

7 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

7 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

7 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq

7 months ago - By: BrainStorm Cell Therapeutics Inc.

BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update